Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of nintedanib plus pemetrexed versus placebo plus pemetrexed in advanced non-squamous non-small cell lung cancer
2008-002072-10Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Non-small cell lung cancer (NS-NSCLC) comparing nintedanib + pemetrexed with placebo + pemetrexed (2 arms). Primary endpoint: Progression-free survival. Started Oct 2008; status: completed.
02
Drugs
nintedanib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2008-002072-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002072-10.